The online version of this article (doi:10.1186/s12890-015-0159-z) contains supplementary material, which is available to authorized users.
This analysis was funded by GSK, and the studies included in the analysis were sponsored by GSK (GSK study numbers HZA106827 [Clinicaltrials.gov registration number: NCT01165138, registered on July 15 2010]; HZA106829 [NCT01134042, May 27, 2010]; HZA106837 [NCT01086384, March 11, 2010]; FFA109685 [NCT00603278, December 27, 2007]; and FFA109687 [NCT00603382, December 27, 2007]).
ASG, CG, MHJ, CSC and LJ are employed by and are shareholders in GSK. YS is employed by GSK. SH has, within the previous 3 years, received honoraria for lectures from Abbott Japan, Astellas Pharma, AstraZeneca, Boehringer Ingelheim, Eisai, GSK, Kyorin Pharmaceutical, Merck, Sharp & Dohme, Novartis Pharma, and Teijin Pharma.
ASG, CG, MHJ, CSC and LJ contributed to the conception and design of this study; CG, SH and YS contributed to the data analysis; and ASG, CG, SH, MHJ, CSC, YS and LJ contributed to the interpretation of the results. All authors were involved in drafting the manuscript, or revising it critically, and have given approval for publication of the final version.
Fluticasone furoate (FF)/vilanterol (VI) is a once daily (OD) inhaled corticosteroid/long-acting β2-agonist combination asthma therapy approved in Japan and the EU. FF/VI efficacy and safety data from asthma studies including patients in East Asia were evaluated to assess ethnic sensitivity.
Randomized, double-blind, multicenter Phase IIb/III trials were assessed. Change from baseline relative to placebo or twice-daily fluticasone propionate 500 μg in trough FEV1 was compared between patients from Japan (N = 148) and Not-Japan (N = 3,066; three studies). Adverse events (AEs), laboratory results, and electrocardiograms were compared between patients from Japan + Korea (N = 188) and Not-Japan + Korea (N = 3,840; five studies).
For trough FEV1, improvements from baseline (least-squares mean difference [95 % confidence interval]) were reported for FF/VI 100/25 μg OD versus placebo at Week 12 (Japan: 0.323 L [0.104–0.542]; Not-Japan: 0.168 L [0.095–0.241]). Improvements from baseline (least-squares mean change [standard error]) were reported with FF/VI 200/25 μg OD at Week 24 (Japan: 0.355 L [0.1152]; Not-Japan: 0.396 L [0.0313]). A greater proportion of patients from Japan + Korea versus Not-Japan + Korea reported AEs in all treatment arms including placebo (FF/VI 100/25 μg: 79 % versus 57 %; FF/VI 200/25 μg: 64 % versus 45 %; placebo: 41 % versus 23 %). There were no notable differences in treatment-related or class-related AEs. No clinically significant changes in electrocardiogram assessments or statistically significant differences in 24 h urinary cortisol excretion were observed between the Japan + Korea and Not-Japan + Korea cohorts.
Good efficacy and an acceptable safety profile were observed for FF/VI 100/25 μg and 200/25 μg OD in East Asian asthma patients; these globally recommended doses are appropriate for asthma patients in Japan.
Additional file 1: Profile of the three Phase III studies included in both the efficacy and safety analyses. (DOCX 47.4 KB)12890_2015_159_MOESM1_ESM.docx
Additional file 2: Profile of the two additional Phase IIb studies included in only the safety analyses. (DOCX 25.6 KB)12890_2015_159_MOESM2_ESM.docx
Additional file 3: List of Institutions and Independent Ethics Committees/Institutional Review Boards for Studies HZA106829, HZA106827, HZA106837, FFA109685, FFA109687 Study HZA106829: 63 Centres. (DOCX 100 KB)12890_2015_159_MOESM3_ESM.docx
Additional file 4: Adjusted treatment differences from baseline in trough FEV1 at Week 12 (Efficacy population). (DOCX 1.49 MB)12890_2015_159_MOESM4_ESM.docx
Additional file 5: Ease of use of the ELLIPTA® dry powder inhaler (DPI; ELLIPTA® is a trademark of the GlaxoSmithKline group of companies). (DOCX 22.5 KB)12890_2015_159_MOESM5_ESM.docx
Additional file 6: Summary of ease of use assessment and responses to questions on the ELLIPTA DPI by patients from Japan (HZA106827 ITT population). (DOCX 25.2 KB)12890_2015_159_MOESM6_ESM.docx
Additional file 7: Summary of exposure in each treatment arm (Safety population). (DOCX 26.5 KB)12890_2015_159_MOESM7_ESM.docx
Additional file 8: AEs reported by ≥3 patients in the Japan+Korea cohort of any relevant treatment arm and the corresponding incidence in the Not-Japan+Korea cohort and the Overall population (Safety population). (DOCX 26.9 KB)12890_2015_159_MOESM8_ESM.docx
Additional file 9: Region ratios of ‘treatment effect’ in Japan+Korea and Not-Japan+Korea patients, where ‘treatment effect’ is the comparison between treatment arms of 24h urinary cortisol excretion ratio (end of treatment/baseline; Urinary Cortisol population). (DOCX 944 KB)12890_2015_159_MOESM9_ESM.docx
Global Initiative for Asthma. Global Burden of Asthma. http://www.ginasthma.org/local/uploads/files/GINABurdenReport_1.pdf. Accessed 21 November 2014.
Global Initiative for Asthma. Global strategy for asthma management and prevention. Updated August 2014. http://www.ginasthma.org/local/uploads/files/GINA_Report_2014_Aug12_1.pdf. Accessed 21 December 2015.
National Institutes of Health (NIH). Guidelines for the Diagnosis and Management of Asthma - Expert Panel Report 3 2007. U.S. Department of Health and Human Services, Bethesda, MD; 2007. http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf.
WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964 and amended (latest) by the 59th WMA General Assembly, Seoul, Korea, October 2008. http://www.wma.net/en/30publications/10policies/b3/index.html. Accessed 14 June 2013.
HUGO Pan-Asian SNP Consortium, Abdulla MA, Ahmed I, Assawamakin A, Bhak J, Brahmachari SK, et al. Mapping human genetic diversity in Asia. Science. 2009;326:1541–5. CrossRef
Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, european community for steel and coal. Official statement of the european respiratory society. Eur Respir J Suppl. 1993;16:5–40. PubMedCrossRef
Cotes JE, Leathart GL. Lung function: assessment and application in medicine. 5th ed. Oxford: Blackwell Scientific Publications; 1993.
Kanmuri K, Narukawa M. Investigation of the safety profiles of Japanese clinical trials. Ther Innov Reg Sci. 2014;48:308–15.
Muraki M, Soutome T, Hashimoto K, Tohda Y. Long-term study of fluticasone furoate/vilanterol combination (FF/VI) and FF alone in Japanese adult patients with bronchial asthma. Allergol Immunol. 2013;20:110–25.
Busse WW, O'Byrne PM, Bleecker ER, Lötvall J, Woodcock A, Andersen L, et al. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β2 agonist vilanterol administered once daily for 52 weeks in patients ≥12 years old with asthma: a randomised trial. Thorax. 2013;68:513–20. PubMedPubMedCentralCrossRef
Woodcock A, Bleecker ER, Lötvall J, O'Byrne PM, Bateman ED, Medley H, et al. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial. Chest. 2013;144:1222–9. PubMedPubMedCentralCrossRef
Allen A. The relationship between fluticasone furoate systemic exposure and cortisol suppression. Clin Pharmacokinetics. 2013;52:885–96. CrossRef
Allen A, Schenkenberger I, Trivedi R, Cole J, Hicks W, Gul N, et al. Inhaled fluticasone furoate/vilanterol does not affect hypothalamic-pituitary-adrenal axis function in adolescent and adult asthma: randomised, double-blind, placebo-controlled study. Clin Respir J. 2013;7:397–406. PubMedPubMedCentralCrossRef
Mehta R, Preece A, Newlands A, Blowers J, Cahn A. Safety, pharmacodynamics (PD) and pharmacokinetics (PK) of darotropium (DARO) and vilanterol (VI) in healthy subjects: two phase 1 studies. Eur Respir J. 2013;42(Suppl. 57):125–6s.
Relvar Ellipta: EPAR – Product Information. 10 December 2013; updated 13 August 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002673/WC500157633.pdf. Accessed 21 November 2014.
- Ethnic sensitivity assessment of fluticasone furoate/vilanterol in East Asian asthma patients from randomized double-blind multicentre Phase IIb/III trials
Annette S. Gross
Mark H. James
Christine S. Clifton
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II